Speakers
Lilian Alcaraz
Sarah Fryer
Marco Delise
Panel
Lilian leads the Early Innovation Partnering team for EMEA through the identification, incubation, due diligence, negotiations, execution and on-boarding of high-impact partnerships and collaborations for J&J. He has experience in sourcing and transacting across a wide range of collaboration and licensing opportunities from small molecule and antibody asset deals, through to platform technologies. Prior to joining J&J, Lilian gained over 18 years’ experience in Drug Discovery as a medicinal chemist at Charles River, Galapagos (Argenta Discovery) and AstraZeneca. Lilian holds a Ph.D. in Organic Chemistry at the ULP (Strasbourg, France), and was a Post-Doctoral Fellow at the University of York (UK).
Sarah Fryer is a Director on the Board of the ICR, a membership-led, not for profit, independent association for clinical research professionals, in commercial and non-commercial environments.
The ICR has three guiding principles: Developing Professionals; Sharing Knowledge; and Raising Standards. It promotes good relations with other healthcare related groups, including the BIA, and provides:
Sarah has worked in clinical development for more than 30 years, with the last 20 years focusing on clinical QA. The majority of her career has been spent working in contract research and consultancy roles, supporting early phase biopharma companies as they move from research into clinical development. She was co-founder of Gregory Fryer Associates and founder of QRC Consultants and is now working as an independent GCP QA consultant as Director of Green End Barns Consulting Ltd.
She has been a long term member of the ICR and is also a Fellow of the Research Quality Assurance and a member of the Royal Society of Biology.
Her particular interest is the importance of quality and regulatory compliance in clinical research and brings this interest with enthusiasm to her role on the Board of the ICR.
Stevenage Bioscience Catalyst (SBC) is one of Europe’s leading clusters of therapeutics startups. At SBC, Marco is responsible for business development and for supporting the business growth of resident companies. His work includes connecting founders with experts, investors, and pharma partners; organising workshops on topics such as storytelling, negotiation, AI tools, and grant writing; and leading the Catalyser programme, which helps therapeutics startups refine their commercialisation strategies.
Before joining SBC in 2022, Marco was part of the founding team of alternative-protein start-up, Better Dairy. As Head of R&D, he led the science team and helped the start-up grow from pre-seed to £22m Series A investment. As Innovation Lead, he organised and managed the building of a new lab and office facility in East London and helped devise new scientific strategies.
Marco holds a BSc and MSc in Biomedical Engineering with a focus on data science. He also holds a PhD in Synthetic Biology with a focus on protein design. Before joining Better Dairy, he was part of the Entrepreneur First programme.
Daniel Pavin advises clients on a wide range of transactions involving intellectual property, technology and data.
He has extensive experience advising pharmaceutical, biotechnology, medical device and technology companies in connection with licensing, collaborations and other strategic agreements. He also advises clients in connection with investments, fundraisings and M&A.
Daniel has a particular focus on digital transformation in the life sciences and healthcare sectors, including digital health transactions, and data-driven and AI drug discovery and development projects.
Daniel is one of the leaders of Covington’s global, multidisciplinary Digital Health Initiative, which brings together the firm’s considerable resources across the broad array of legal, regulatory, commercial, and policy issues relating to the development and exploitation of digital health products and services.